Report Examines Pros, Cons of Orphan Drug Status

Report Examines Pros, Cons of Orphan Drug Status

291224

Report Examines Pros, Cons of Orphan Drug Status

The Orphan Drug Act (ODA) has spurred the development of treatments for rare diseases, such as Lambert-Eaton myasthenic syndrome (LEMS), according to a recent report. Yet, patient advocates say that a better balance between development incentives and competition might benefit the rare disease community. The report, “Orphan Drugs in the United States: An Examination of Patents and Orphan Drug Exclusivity,” was commissioned by the National Organization for Rare Disorders (NORD) and conducted by Avalere Health,…

You must be logged in to read/download the full post.